LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

LLY

1,063.12

+0.04%↑

JNJ

208.77

-0.11%↓

ABBV

226.66

+0.74%↑

UNH

333.66

+1.65%↑

AZN

91.6

+0.91%↑

Search

Artivion Inc

Abierto

SectorSalud

46.96 -0.93

Resumen

Variación precio

24h

Actual

Mínimo

46.19

Máximo

47.72

Métricas clave

By Trading Economics

Ingresos

-14M

6.5M

Ventas

416K

113M

BPA

0.16

Margen de beneficio

5.734

Empleados

1,600

EBITDA

2.6M

19M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+9.67% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-6.4M

2.1B

Apertura anterior

47.89

Cierre anterior

46.96

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

40 / 374 Clasificación en Healthcare

Artivion Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 dic 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Ganancias

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Ganancias

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Charlas de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Charlas de Mercado
Ganancias

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Adquisiciones, fusiones, absorciones

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Ganancias

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev $1.42B >NKE

Comparación entre iguales

Cambio de precio

Artivion Inc Esperado

Precio Objetivo

By TipRanks

9.67% repunte

Estimación a 12 meses

Media 51.71 USD  9.67%

Máximo 58 USD

Mínimo 40 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

40 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat